Resumen:
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunc-tion with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. (C) 2017 AACR.